[go: up one dir, main page]

DK1658047T3 - Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet - Google Patents

Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet

Info

Publication number
DK1658047T3
DK1658047T3 DK04764317T DK04764317T DK1658047T3 DK 1658047 T3 DK1658047 T3 DK 1658047T3 DK 04764317 T DK04764317 T DK 04764317T DK 04764317 T DK04764317 T DK 04764317T DK 1658047 T3 DK1658047 T3 DK 1658047T3
Authority
DK
Denmark
Prior art keywords
storage stability
residual moisture
excellent storage
amorphous powder
low residual
Prior art date
Application number
DK04764317T
Other languages
Danish (da)
English (en)
Inventor
Karoline Bechtold-Peters
Wolfgang Friess
Stefanie Schuele
Stefan Bassarab
Patrick Garidel
Torsten Schultz-Fademrecht
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1658047T3 publication Critical patent/DK1658047T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
DK04764317T 2003-08-22 2004-08-20 Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet DK1658047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10339197A DE10339197A1 (de) 2003-08-22 2003-08-22 Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
PCT/EP2004/009333 WO2005020953A1 (de) 2003-08-22 2004-08-20 Sprühgetrocknete amorphe pulver mit geringer restfeuchte und guter lagerstabilität

Publications (1)

Publication Number Publication Date
DK1658047T3 true DK1658047T3 (da) 2008-06-16

Family

ID=34202048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04764317T DK1658047T3 (da) 2003-08-22 2004-08-20 Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet

Country Status (11)

Country Link
US (1) US20070298116A1 (es)
EP (1) EP1658047B1 (es)
JP (1) JP2007503380A (es)
KR (1) KR20070054590A (es)
AT (1) ATE388688T1 (es)
CA (1) CA2536319A1 (es)
DE (2) DE10339197A1 (es)
DK (1) DK1658047T3 (es)
ES (1) ES2302021T3 (es)
TW (1) TW200517142A (es)
WO (1) WO2005020953A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102006023770A1 (de) * 2006-05-20 2007-11-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treibgasfreie Aerosolformulierung für die Inhalation
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
PT103743B (pt) * 2007-05-16 2013-01-15 Hovione Farmaciencia S A Processo para preparar derivados de 21-disódio fosfato de pregnanos.
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP6078217B2 (ja) * 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
JP2012509922A (ja) * 2008-11-27 2012-04-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規粉末化結晶質吸入薬
JP5671001B2 (ja) * 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
EP2662472B1 (de) 2009-03-31 2019-02-27 Boehringer Ingelheim International Gmbh Verfahren zur Beschichtung einer Oberfläche eines Bauteils
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
EP2432531B1 (de) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
KR101782306B1 (ko) 2009-11-25 2017-09-27 베링거 인겔하임 인터내셔날 게엠베하 분무기
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
ES2775104T5 (es) 2011-11-18 2023-06-08 Regeneron Pharma Método de fabricación de una formulación farmacéutica de liberación prolongada que comprende micropartículas de proteínas recubiertas de polímero utilizando secado por pulverización
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
DE202013012829U1 (de) 2012-06-14 2020-03-04 Glycom A/S Verbesserung der Stabilität und Reinheit sowie Erhöhung der Bioverfügbarkeit von menschlichen Milch-Oligosacchariden oder Vorläufern oder Mischungen davon
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
MX380824B (es) 2014-05-07 2025-03-12 Boehringer Ingelheim Int Nebulizador y recipiente.
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
AU2016369557B2 (en) * 2015-12-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
WO2019012461A1 (en) 2017-07-12 2019-01-17 Glycom A/S AMORPHOUS MIXTURE COMPRISING A NEUTRAL MONO- OR OLIGOSACCHARIDE AND A NON-GLUCIDIC ACID COMPONENT
KR20240104926A (ko) 2022-12-28 2024-07-05 씨제이제일제당 (주) 발효 제품 제조 방법
TW202440065A (zh) * 2022-12-28 2024-10-16 日商中外製藥股份有限公司 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
PL319600A1 (en) * 1994-09-29 1997-08-18 Andaris Ltd Spray-dried microparticles as therapeutic carriers
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
TWI310688B (en) * 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
CN1438874A (zh) * 2000-06-08 2003-08-27 宝德杰克特疫苗有限公司 粉末组合物
DE60127175T2 (de) * 2000-12-21 2007-11-08 Nektar Therapeutics, San Carlos Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
WO2002101412A2 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
US20030186271A1 (en) * 2001-11-19 2003-10-02 Robin Hwang Pharmaceutical compositions in particulate form
MXPA04009673A (es) * 2002-04-03 2005-01-11 Solvay Pharm Bv Formulacion de cannabinoide natural estabilizado.
AU2003221888B2 (en) * 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying

Also Published As

Publication number Publication date
KR20070054590A (ko) 2007-05-29
WO2005020953A1 (de) 2005-03-10
CA2536319A1 (en) 2005-03-10
US20070298116A1 (en) 2007-12-27
TW200517142A (en) 2005-06-01
EP1658047A1 (de) 2006-05-24
DE10339197A1 (de) 2005-03-24
JP2007503380A (ja) 2007-02-22
DE502004006512D1 (de) 2008-04-24
ES2302021T3 (es) 2008-07-01
EP1658047B1 (de) 2008-03-12
ATE388688T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
DK1658047T3 (da) Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
WO2005039499A3 (en) Rapidly disintegrating film
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
IL186655A0 (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
WO2008035020A3 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
WO2008013929A3 (en) Anti-migraine oral spray formulations and methods
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
TNSN06277A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
EA200301275A1 (ru) Капсулы для ингаляции
CN101829036A (zh) 口腔喷雾剂
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
MY131488A (en) Low dose liquid entecavir formulations and use
WO2004075824A8 (en) Pharmaceutical compositions for nasal delivery
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
WO2005065639A3 (en) Novel pharmaceutical compositions
NO20044497L (no) Torr pulver sammensetninger
WO2005065429B1 (en) Composition and method for treatment of hepatic encephalopathy
US9427421B2 (en) Effervescent compositions containing N-acetylcysteine
WO2005041922A3 (en) Composition
NZ547376A (en) Transdermal pharmaceutical spray formulations comprising a VP/VA copolymer and a non-aqueous vehicle
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2002043693A3 (en) Pharmaceutical compositions for inhalation